跳至主要内容
临床试验/2026-526314-90-00
2026-526314-90-00招募中4 期

Unprescribing the Pill to Reassess Symptom and Cognitive Recovery in Depression (UNPRESCRIB-D)

Region Hovedstaden1 个研究点 分布在 1 个国家目标入组 106 人开始时间: 2026年6月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
106
试验地点
1
主要终点
The mean Hamilton Depressive Rating Scale 6-item (HRDS-6) score

研究概览

简要总结

The primary objectives are to determine if COC discontinuation (COCd) compared with COC continuation (COCc) affects (i) antidepressant treatment outcome and (ii) verbal memory performance at week 8 under concomitant pharmacological antidepressant treatment.

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
性别
Female
接受健康志愿者

入选标准

  • Female biological sex
  • Age 18-39 years
  • Current user of combined oral contraception, which was started at least one month prior to inclusion
  • Fulfillment of ICD-10 for primary moderate to severe unipolar depressive episode (i.e., not secondary to organic or other psychiatric disorder), for which treatment with SSRI monotherapy is clinically indicated.

排除标准

  • Acute suicidality
  • Duration of depressive episode exceeding 2 years
  • Severe somatic disease or traumatic brain injury
  • Pregnancy or breastfeeding or any plan to become pregnant within the next 3 months
  • Menopause, perimenopause or use of hormonal replacement therapy
  • Insufficient Danish language skills to complete cognitive and psychometric testing
  • Contraindication for use of Femicept
  • Moderate to severe gynecological conditions in which COCs are recommended as standard treatment, including endometriosis, severe dysmenorrhea, severe acne, menorrhagia associated with anemia, and polycystic ovary syndrome.
  • Additional exclusion criteria for participants volunteering for MRI and MRI/PET scan program: Contraindications for MRI (e.g. metal implants or claustrophobia)
  • Additional exclusion criteria for participants volunteering for MRI/PET scan program: Participation in experiments with exposure to radioactivity (> 10 mSv) within the last year of significant occupational exposure to radioactivity (only participants volunteering for the MRI/PET scan program)
  • Additional exclusion criteria for participants volunteering for MRI and MRI/PET scan program: Use of prescription drugs with known serotonergic effects within 2 months of inclusion, including sertraline and other antidepressants
  • Prior or current schizophrenia diagnosis or psychosis/psychotic symptoms
  • Alcohol and substance use disorders
  • Other psychiatric disorder requiring other treatments than SSRI
  • Contraindication for use of sertraline and duloxetine
  • Other current antidepressant treatment, including psychotherapy, than sertraline
  • Use of sertraline for more than 1 month at inclusion
  • Other antidepressant drug treatment attempt in current depressive episode
  • Known non-responder to SSRI

结局指标

主要结局

The mean Hamilton Depressive Rating Scale 6-item (HRDS-6) score

The mean Hamilton Depressive Rating Scale 6-item (HRDS-6) score

The mean total Verbal Affective Memory Task 24 (VAMT-24) recall score calculated as the average score across the immediate (0-24), short- (0-24), and long-term (0-24) recall

The mean total Verbal Affective Memory Task 24 (VAMT-24) recall score calculated as the average score across the immediate (0-24), short- (0-24), and long-term (0-24) recall

次要结局

  • Antidepressant treatment titration rank as defined in the protocol
  • Mean HRDS-6 score
  • The mean total Rey- Auditory Verbal Learning Test (RAVLT) recall score calculated as the average score across the immediate (0-15), short- (0-15), and long-term (0-15) recall
  • Domain-specific end point 1: Mean striatal 5-HT4R non-displaceable binding potential (BPND) as measured by positron emission tomography
  • Domain-specific end point 2a: Mean hypothalamic blood flow response to oral glucose as a proxy for brain insulin sensitivity
  • Domain-specific end point 2b: Mean hypothalamic blood-oxygen-level-dependent response to oral glucose
  • Domain-specific end point 2c: Mean Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) as a measure for peripheral insulin sensitivity
  • Domain-specific end point 3: Mean cortisol awakening response
  • Domain-specific end point 4a: Mean extra-neurite mean diffusivity as a proxy for brain inflammation
  • Domain-specific end point 4b: Mean hcCRP as a measure of peripheral inflammation
  • Domain-specific end point 4c: kynurenic acid/quinolinic acid ratio (neuroprotective index)
  • Domain-specific end point 5: Mean hippocampal activation as measured by functional magnetic resonance imaging (fMRI) during a memory encoding paradigm
  • Domain-specific end point 6a: Mean Element of Desire score
  • Domain-specific end point 6b: Mean ventral striatal activation as measured by fMRI during a monetary reward paradigm
  • Domain-specific end point 7: Mean General Anxiety Disorder-7 score
  • Domain-specific end point 8: Mean resting state functional connectivity as measured with resting state fMRI
  • Domain-specific end point 9: Mean hippocampal gray matter volume as measured with magnetic resonance imaging (MRI)
  • Domain-specific end point 10a: Gut microbiome composition
  • Domain-specific end point 10b: Mean gut microbiome-derived metabolites
  • Domain-specific end point 11: Mean Pittsburgh Sleep Quality Index score
  • Domain-specific end point 12a: Mean Major Depression Inventory (MDI) score
  • Domain-specific end point 12b: Mean HRDS-6 score
  • Domain-specific end point 12c: Treatment titration rank (defined in the protocol)
  • Domain-specific end point 12d: Time to remission
  • Domain-specific end point 12e: Time to hospitalization, suicide, suicide attempt, or treatment switches/add-on

研究者

发起方
Region Hovedstaden
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Søren Vinther Larsen

Scientific

Region Hovedstaden

研究点 (1)

Loading locations...

相似试验

UNPRESCRIB-D | 临床试验